EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Mineralocorticoid replacement therapy in salt‐wasting congenital adrenal hyperplasia

Katharina Lang, Marcus Quinkler, Tina Kienitz

Clinical Endocrinology · 2024-10 · 101 (4) · 346-358

DOI: 10.1111/cen.14959 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Endocrinology, online erschienen am 11.08.2023. Verfasst von Katharina Lang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology in Charlottenburg, Berlin, Germany. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Mineralocorticoids, Hormone Replacement Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with salt‐wasting congenital adrenal hyperplasia (SW‐CAH) usually show pronounced impairment of aldosterone secretion and, therefore, also require mineralocorticoid replacement. While a lot of research and discussion focusses on the glucocorticoid therapy in SW‐CAH to replace the missing cortisol and to control adrenal androgen excess, very little research is dealing with mineralocorticoid replacement. However, recent data demonstrated an increased cardiovascular risk in adult CAH patients urging to reflect also on the current mineralocorticoid replacement therapy. In this review, we explain the role and function of the mineralocorticoid receptor, its ligands and inhibitors and its relevance for the therapy of patients with SW‐CAH. We performed an extensive literature search and present data on mineralocorticoid therapy in SW‐CAH patients as well as clinical advice how to monitor and optimise mineralocorticoid replacement therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalMineralocorticoidsHormone Replacement TherapyHumansReceptors, MineralocorticoidMineralocorticoid Receptor Antagonists

Stichwörter der Autor:innen

17‐hydroxy‐progesteroneadrenal insufficiencyandrostenedionefludrocortisonehydrocortisone

Substanzen

MineralocorticoidsReceptors, MineralocorticoidMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Endocrinology in Charlottenburg, Berlin, Germany.
  • Department of Endocrinology and Metabolism, Charite-Universitätsmedizin, Campus Mitte, Berlin, Germany.

Zitieren

APA

Lang, K., Quinkler, M., & Kienitz, T. (2024). Mineralocorticoid replacement therapy in salt‐wasting congenital adrenal hyperplasia. Clinical Endocrinology, 101(4), 346-358. https://doi.org/10.1111/cen.14959

Vancouver

Lang K, Quinkler M, Kienitz T. Mineralocorticoid replacement therapy in salt‐wasting congenital adrenal hyperplasia. Clinical Endocrinology. 2024;101(4):346-358. doi:10.1111/cen.14959

BibTeX
@article{Lang2024,
  author = {Lang, Katharina and Quinkler, Marcus and Kienitz, Tina},
  title = {Mineralocorticoid replacement therapy in salt‐wasting congenital adrenal hyperplasia},
  journal = {Clinical Endocrinology},
  year = {2024},
  volume = {101},
  number = {4},
  pages = {346--358},
  doi = {10.1111/cen.14959}
}
Kostenlos starten →